Following a story · 2 updates
FTC finalizes insulin antitrust settlement with CVS Caremark
Jul 15, 2026 – Aug 1, 2026
-
FTC settles insulin pricing antitrust case with CVS Caremark for up to $8.5 billion in savings
The FTC settled its antitrust case against CVS Caremark over rebating practices it said inflated insulin list prices, securing up to 8.5 billion dollars in projected consumer savings over 10 years and a new 25 dollar monthly insulin cap program.
Read this issue → -
FTC finalizes insulin antitrust settlement with CVS Caremark
The FTC's July 14, 2026 order bars Caremark from disadvantaging low list price insulin, requires a rebate pass through option, and projects up to 8.5 billion dollars in patient savings over 10 years, leaving Optum Rx as the only Big Three PBM without a final order.
Read this issue →